Dyne Therapeutics
Dyne describes its FORCE platform as a transferrin-receptor-binding Fab, linker, and therapeutic payload for muscle and CNS delivery. Oligonucleotide conjugation and candidate-specific clinical results should be assessed separately.
Corporate information
- Company entity
- Dyne Therapeutics
- Headquarters / principal office
- Waltham, Massachusetts, United States ↗
- Founded
- 2017 ↗
- Ownership / capital status
- Publicly tradedNasdaq-listed: DYN ↗
- Official corporate reference
- https://www.dyne-tx.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Dyne describes its FORCE platform as a transferrin-receptor-binding Fab, linker, and therapeutic payload for muscle and CNS delivery. Oligonucleotide conjugation and candidate-specific clinical results should be assessed separately.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.